Pharmacogenetics: Opportunities for the All of Us Research Program and Other Large Data Sets to Advance the Field.

IF 13.1 1区 医学 Q1 PHARMACOLOGY & PHARMACY Annual review of pharmacology and toxicology Pub Date : 2025-01-01 DOI:10.1146/annurev-pharmtox-061724-080718
Philip E Empey, Jason H Karnes, Julie A Johnson
{"title":"Pharmacogenetics: Opportunities for the <i>All of Us</i> Research Program and Other Large Data Sets to Advance the Field.","authors":"Philip E Empey, Jason H Karnes, Julie A Johnson","doi":"10.1146/annurev-pharmtox-061724-080718","DOIUrl":null,"url":null,"abstract":"<p><p>Pharmacogenetic variation is common and an established driver of response for many drugs. There has been tremendous progress in pharmacogenetics knowledge over the last 30 years and in clinical implementation of that knowledge over the last 15 years. But there have also been many examples where translation has stalled because of the lack of available data sets for discovery or validation research. The recent availability of data from very large cohorts with linked genetic, electronic health record, and other data promises new opportunities to advance pharmacogenetics research. This review presents the stages from pharmacogenetics discovery to widespread clinical adoption using prominent gene-drug pairs that have been implemented into clinical practice as examples. We discuss the opportunities that the <i>All of Us</i> Research Program and other large biorepositories with genomic and linked electronic health record data present in advancing and accelerating the translation of pharmacogenetics into clinical practice.</p>","PeriodicalId":8057,"journal":{"name":"Annual review of pharmacology and toxicology","volume":"65 1","pages":"111-130"},"PeriodicalIF":13.1000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12262141/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annual review of pharmacology and toxicology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1146/annurev-pharmtox-061724-080718","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Pharmacogenetic variation is common and an established driver of response for many drugs. There has been tremendous progress in pharmacogenetics knowledge over the last 30 years and in clinical implementation of that knowledge over the last 15 years. But there have also been many examples where translation has stalled because of the lack of available data sets for discovery or validation research. The recent availability of data from very large cohorts with linked genetic, electronic health record, and other data promises new opportunities to advance pharmacogenetics research. This review presents the stages from pharmacogenetics discovery to widespread clinical adoption using prominent gene-drug pairs that have been implemented into clinical practice as examples. We discuss the opportunities that the All of Us Research Program and other large biorepositories with genomic and linked electronic health record data present in advancing and accelerating the translation of pharmacogenetics into clinical practice.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
药物遗传学:我们所有人的研究计划和其他大型数据集推进该领域的机会。
药物遗传变异是常见的,并且是许多药物反应的既定驱动因素。在过去的30年里,药物遗传学知识取得了巨大的进步,在过去的15年里,这些知识的临床应用也取得了巨大的进步。但也有很多例子表明,由于缺乏可用于发现或验证研究的数据集,翻译陷入了停滞。最近有大量数据来自相关的遗传、电子健康记录和其他数据,为推进药物遗传学研究提供了新的机会。这篇综述介绍了从药物遗传学发现到广泛临床采用的阶段,并以临床实践中实施的突出基因-药物对为例。我们讨论了“我们所有人”研究计划和其他具有基因组和相关电子健康记录数据的大型生物储库在推进和加速药物遗传学转化为临床实践中的机会。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
27.80
自引率
0.00%
发文量
53
期刊介绍: Since 1961, the Annual Review of Pharmacology and Toxicology has been a comprehensive resource covering significant developments in pharmacology and toxicology. The journal encompasses various aspects, including receptors, transporters, enzymes, chemical agents, drug development science, and systems like the immune, nervous, gastrointestinal, cardiovascular, endocrine, and pulmonary systems. Special topics are also featured in this annual review.
期刊最新文献
A Change of Mind: Targeting Amyloid-β with Better Safety Profile. Human Mutations in the TRPV1 Channel: Implications for Noxious Cold Sensation. Lessons from Glucocorticoids, Metformin, and Dimethyl Fumarate: Could Targeting Immunometabolism Lead to Better Anti-Inflammatory Therapies? A Common Adverse Outcome Pathway for Metal(loid)s Inducing Nephrotoxicity to Advance Next-Generation Risk Assessment of Chemical Mixtures. RNA Splicing as a Therapeutic Target in Cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1